 CAMBRIDGE, Mass., Oct. 29, 2020 GLOBE NEWSWIRE -- Rubius Therapeutics, Inc. Nasdaq:RUBY, a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell TherapeuticsTM, today announced plans to report third quarter 2020 financial results on Monday, November 9, 2020, before market open. 